Emerging biopharma and biotech companies are frequently faced with complex challenges related to the design, launch and operations associated with a new clinical development program. Historically, small-company clinical programs have had a lower rate of success than their larger counterparts due to a variety of reported factors such as limited internal resources, lack of infrastructure, delays in manufacturing and clinical supply, and funding concerns. SCOPE’s Building New Clinical Programs, Teams, and Ops in Small Biopharma track is designed to share the experiences and successes of emerging biopharma and biotech executives as they build and launch their clinical programs. The Clinical Ops for Novel Modalities track explores some of the key complexities when running cell and gene therapy trials.